490 related articles for article (PubMed ID: 19920716)
1. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Group.
Apolone G; Corli O; Negri E; Mangano S; Montanari M; Greco MT; ; Apolone G; Bertetto O; Caraceni A; Corli O; De Conno F; Labianca R; Maltoni M; Nicora Maria F; Torri V; Zucco F
Clin J Pain; 2009 Oct; 25(8):671-82. PubMed ID: 19920716
[TBL] [Abstract][Full Text] [Related]
2. [Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group].
Greco MT; Deandrea S; Corli O; Montanari M; Caraceni A; Apolone G;
Recenti Prog Med; 2008 Nov; 99(11):538-51. PubMed ID: 19209537
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
4. Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study.
Sorge J; Sittl R
Clin Ther; 2004 Nov; 26(11):1808-20. PubMed ID: 15639693
[TBL] [Abstract][Full Text] [Related]
5. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
6. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
[TBL] [Abstract][Full Text] [Related]
7. Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients.
Griessinger N; Sittl R; Likar R
Curr Med Res Opin; 2005 Aug; 21(8):1147-56. PubMed ID: 16083522
[TBL] [Abstract][Full Text] [Related]
8. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
9. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
11. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
12. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.
Mercadante S; Porzio G; Fulfaro F; Aielli F; Verna L; Ficorella C; Casuccio A; Riina S; Intravaia G; Mangione S
J Pain Symptom Manage; 2007 Nov; 34(5):532-8. PubMed ID: 17629666
[TBL] [Abstract][Full Text] [Related]
13. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
[TBL] [Abstract][Full Text] [Related]
14. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
15. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
16. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA
Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396
[TBL] [Abstract][Full Text] [Related]
17. Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies.
Penza P; Campanella A; Martini A; Melli G; Lombardi R; Camozzi F; Devigili G; Lauria G
J Peripher Nerv Syst; 2008 Dec; 13(4):283-8. PubMed ID: 19192068
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine TDS: the clinical development rationale and results.
Radbruch L; Vielvoye-Kerkmeer A
Int J Clin Pract Suppl; 2003 Feb; (133):15-8; discussion 23-4. PubMed ID: 12665119
[TBL] [Abstract][Full Text] [Related]
19. Transdermal buprenorphine in cancer pain and palliative care.
Sittl R
Palliat Med; 2006; 20 Suppl 1():s25-30. PubMed ID: 16764218
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the seven-day buprenorphine transdermal system in opioid-naïve patients with moderate to severe chronic low back pain: an enriched, randomized, double-blind, placebo-controlled study.
Steiner DJ; Sitar S; Wen W; Sawyerr G; Munera C; Ripa SR; Landau C
J Pain Symptom Manage; 2011 Dec; 42(6):903-17. PubMed ID: 21945130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]